

Further Studies on Synthesis of the 12,13-*seco* Norditerpenoid Alkaloids

Qiao-Hong CHEN and Feng-Peng WANG*

Department of Chemistry of Medicinal Natural Products, West China College of Pharmacy, Sichuan University; No. 17, Duan 3, Renmin Nan Road, Chengdu 610041, P. R. China. Received March 29, 2002; accepted June 4, 2002

After a series of optimization for the reaction conditions (reagents, reaction temperature, etc.), treatment of the sulfonates **4**, **8**, **13** and **15** with 8% NaOH (room temperature, 24 h) via a semipinacol rearrangement afforded the corresponding C-nor compounds **5**, **9**, **12** and **16**, as the major of a pair of epimer at C-16, to an excellent extent, in 95%, 92%, 100% and 90% yield, respectively. The 12,13-*seco* compounds **21** and **22** (**23**) were obtained in 20% and 60% yield, respectively, by treating **5** with Br₂-glacial HOAc (room temperature, 24 h). Treatment of the C-nor compounds **5** or **6**, **16** or **17**, and **28** from **10** with SOCl₂-anhydrous benzene (room temperature, overnight) afforded the 12,13-*seco* compounds **24**, **26** and **30** in 70% or 100%, 40% and 66% yield, respectively. When treatment of the C-nor compound **29** from **9** under same conditions gave the 12,13-*seco* products **30**, **31** and **32** in 33%, 26% and 20% yield. When treating **21** or **24**, and **26** with 5% KOH in EtOH afforded the 12,13-*seco* compounds **25** and **27** quantitatively, respectively. The compound **31** converted to **30** quantitatively by treatment with Na₂CO₃ in MeOH. All of the new compounds were isolated and fully characterized.

Key words norditerpenoid alkaloid; yunaconitine; 12,13-*seco* norditerpenoid alkaloid

In the previous paper of this series,¹⁾ we reported the synthesis of the 12,13-*seco* norditerpenoid alkaloids from the norditerpenoid alkaloids. This is the key stage in the modification of the norditerpenoid alkaloids for evaluation of their biological activities. Herein, we have continued to describe in detail the further synthesis of the 12,13-*seco* norditerpenoid alkaloids.



Results and Discussion

In our investigation toward the modification of the bioactive norditerpenoid alkaloids, the synthesis of 12,13-*seco* norditerpenoid alkaloids is one of most difficult steps, which has not been reported in the literature before. After a series of unsuccessful experiments,^{2,3)} we finally found that the 12,13-*seco* norditerpenoid alkaloids can be synthesized via a semipinacol rearrangement followed by reaction with Br₂-HOAc.¹⁾ This is the first novel access to the 12,13-*seco* norditerpenoid alkaloid recently reported by us.

To investigate further the effect of the A ring structures on the reaction, we have prepared a series of C-nor compounds (Chart 1), with different structural moieties of the A ring. The α,β -unsaturated ketone methyl sulfonate **4**, C₂₅H₃₇NO₉S (high resolution electron impact (HR-EI)-MS), was obtained using yunaconitine **1**⁴⁾ as the starting material via **2**⁴⁾ and **3** in three steps in nearly quantitative overall yields (Chart 2). The ¹H- and ¹³C-NMR spectra of **4** indicated the presence of an α,β -unsaturated ketone moiety (δ_{H} 6.20, 6.37, each 1H, d, $J=10.2$ Hz; δ_{C} 146.6 d, 132.0 d, 200.4 s) and a methylsulfonyl group (δ_{H} 3.11, 3H s; δ_{C} 38.5 q) which can be assigned at C-14 due to observation of the one-proton signal at δ_{H} 4.75 (d, $J=6.2$ Hz), attributable to H-14 β . The reaction of **4** with NaOH was carried out in *N,N*-dimethylformamide (DMF) at 150 °C for 6.5 h to give compounds **5** and **6** as a pair of epimers in 68% and 5% yield, respectively. Both compounds **5** and **6** have the same molecular formula C₂₄H₃₃NO₆ (HR-EI-MS). The ¹H- and ¹³C-NMR spectra of **5** and **6** showed three aliphatic methoxyl groups (δ_{H} 3.26, 3.40, 3.48, each 3H, s; δ_{C} 58.2 q, 58.3 q, 59.0 q for **5**; δ_{H} 3.25, 3.34, 3.37, each 3H, s; δ_{C} 58.0 q, 58.4 q, 58.9 q for **6**), a carbonyl group (δ_{C} 211.6, s for **5**; δ_{C} 212.1 s for **6**) and an α,β -unsat-


urated ketone (δ_{H} 6.21, 6.26, each 1H, d, $J=10.0$ Hz; δ_{C} 144.9 d, 132.4 d, 200.6 s for **5**; δ_{H} 6.19, 6.26, each 1H, d, $J=10.0$ Hz; δ_{C} 145.1 d, 132.2 d, 200.8 s for **6**). Their structures were determined on the basis of spectra compared, in particular, with compounds **9**¹⁾ and **10**¹⁾ which were obtained from **8**.¹⁾ The δ values of H-1 in the ¹H-NMR spectra of compounds **4**, **5** and **6** displayed higher than the general cyclohexenone, possibly due to the presence of a steric hindrance between H-1 and H-12 α in these rigid molecules. Similarly, when compound **3** was subjected to treatment subsequently through reduction with H₂/Pd-C, sulfonation and semipinacol rearrangement, another pair of the C-nor compounds **12** and **14** in 37% and 10% yield, respectively, were afforded (Chart 3). Both compounds **12** and **14** have the same molecular formula C₂₄H₃₅NO₆ (HR-EI-MS). Their ¹H- and ¹³C-NMR spectra showed the absence of OMs group but two carbonyl groups (δ_{H} 216.9 s, 212.2 s for **12**; δ_{C} 217.2 s, 212.7 s for **14**). The structures of **12** and **14** were confirmed on the basis of comparison of the NMR spectra with those of the analogues such **5**, **6**, **9** and **10** (Table 1). When the same reaction conditions were applied to **15** from the 3-ketone **13** by protection with ethylene glycol, 48% and 10% yields of compounds **16** and **17**, respectively, were also obtained as a pair of epimers (Chart 4). Their structures were also confirmed by comparison of the NMR spectra with the analogues **5**, **6**, **9**, **10**, **12** and **14** (Table 1). It should be noted that we have synthesized the C-nor compounds **5/6**, **9/10**, **12/14** and **16/17**, as epimeric pairs at C-16, only in moderate yields (37—70%). It is apparent that this is possibly due to the vigorous reaction conditions (NaOH, high temperature). However, the attempt to enhance the yields of the resulting products using **8** in pyridine as the starting material at 140 °C for 12 h resulted in the formation of the compounds **9** and **10** in poor yields (3%, 18%, respectively). This implies that the strong base, e.g., NaOH, is necessary for a semipinacol rearrangement. After a series of optimization for the reaction conditions, we have fortunately found that reactions of the compounds **4**, **8**, **13** and **15** with 8% NaOH carried out under the standard conditions in methanol at room temperature for 24 h gave the corresponding C-nor products **5**, **9**, **12** and **16**,

* To whom correspondence should be addressed. e-mail: wfp@wcums.edu.cn





a). 3 equiv. MsCl/pyridine, r.t (~80% yield); b). method A: DMF/NaOH, 150°C, 14h (~68% yield); method B: 8% NaOH in MeOH, rt, 24h (90–100% yield)
 c). Br₂ (1.2 equiv) in HOAc, rt, 1.5h or 1h; d). Br₂ (2.0 equiv) in HOAc, rt, 2h.

Chart 1



a). Jones reagent, 0°C, 20 min; b). 5% NaOH, in MeOH, 55°C, 0.5h; c). MsCl-Pyridine, rt, 4h; d). method A: NaOH in DMF, 150°C, 6.5h; (**5**: 68%; **6**: 5%); method B: 8% NaOH in MeOH, rt, 24h (**5**: 95%; **6**: no detected).

Chart 2



a). H₂, Pd/C; b). MsCl-pyridine, 40°C, 1.5h; c). method A: NaOH in DMF, 150°C, 12h (**12**: 37%; **14**: 10%); method B: 8% NaOH in MeOH, rt, 24h (**12**: 100%; **14**: no detected)

Chart 3


Table 1. ¹³C-NMR Data of Compounds **5**, **6**, **9**, **10**, **12**, **14**, **16** and **17**

No.	5	6	9	10	12	14	16	17
1	144.9 d	145.1 d	80.9	81.0	22.6 t	22.7 t	25.1 t	25.5 t
2	132.4 d	132.2 d	34.4	34.3	38.5 t	38.7 t	30.9 t	31.0 t
3	200.6 s	200.8 s	71.6	72.0	216.9 s	217.2 s	112.7 s	112.9 s
4	47.2 s	47.0 s	42.2	42.4	43.4 s	43.4 s	43.3 s	43.3 s
5	48.1 d	48.4 d	47.3	47.6	44.1 d	44.5 d	46.1 d	47.0 d
6	83.0 d	82.5 d	83.5	82.9	83.8 d	83.4 d	84.1 d	84.0 d
7	52.2 d	50.4 d	52.0	50.3	51.5 d	49.9 d	51.7 d	50.1 d
8	77.3 s	74.0 s	76.5	72.7	77.3 s	74.1 s	76.9 s	73.9 s
9	43.8 d	46.7 d	43.7	46.8	44.0 d	47.2 d	44.0 d	46.4 d
10	40.2 d	40.8 d	44.5	44.3	42.8 d	43.5 d	43.5 d	44.0 d
11	50.4 s	50.4 s	47.8	47.8	52.4 s	52.5 s	45.1 s	45.1 s
12	27.4 t	28.0 t	30.6	31.3	27.1 t	27.7 t	27.5 t	28.1 t
13	211.6 s	212.1 s	211.1	208.7	212.2 s	212.7 s	212.4 s	212.7 s
14	37.7 d	35.3 d	38.8	36.3	37.6 d	35.3 d	38.1 d	35.7 d
15	42.2 t	40.3 t	39.8	37.5	42.1 t	40.5 t	41.6 t	39.9 t
16	79.1 d	81.9 d	79.1	80.7	79.1 d	82.2 d	79.2 d	82.0 d
17	61.5 d	61.2 d	61.5	61.5	66.1 d	66.0 d	65.0 d	64.8 d
18	71.6 t	71.8 t	76.1	76.9	74.4 t	74.7 t	73.1 t	73.2 t
19	48.7 t	48.6 t	46.7	46.9	48.6 t	48.5 t	48.6 t	48.5 t
21	50.9 t	50.9 t	48.6	48.7	52.2 t	52.3 t	50.2 t	50.2 t
22	12.8 q	12.8 q	13.2	13.1	12.9 q	13.0 q	13.1 q	13.0 q
1'	—	—	55.9	55.8	—	—	—	—
6'	58.2 q	58.0 q	58.1	57.7	58.0 q	57.9 q	58.0 q	58.0 q
16'	58.3 q	58.4 q	58.1	58.1	58.1 q	58.3 q	58.2 q	58.2 q
18'	59.0 q	58.9 q	59.0	59.1	58.9 q	58.9 q	58.7 q	58.9 q
O-CH ₂	—	—	—	—	—	—	64.3 t	64.3 t
O-CH ₂	—	—	—	—	—	—	65.2 t	65.7 t

to an excellent extent, in 95%, 92%, 100% and 90% yield, respectively. Therefore, this successful optimization provided a good base for us to further synthesize the final 12,13-*seco* products *via* cleavage of the C(12)–C(14) bond of the C-nor compounds. In addition to the context of this discussion on the semipinacol rearrangement, it is of interest to note that only the major one of two spots on TLC of the resulting products before work-up were observed but finally obtaining the major products bearing the 16α-methoxyl groups, apparently by an epimerization process under the alkaline conditions from the 16β-OCH₃ group to the 16α-OCH₃ group.



This is plausible for the C-nor compounds bearing the 16α-OCH₃ group without the de-stabilizing interaction between the 16-OCH₃ and the 8β-OH group.

Recently, we reported the preparation of the key intermediates **18**, **19** and **20** using different eq of Br₂ in HOAc from **9** in 40%, 29% and 10% yield, respectively.¹⁾ But, the results



a). glycol/anhydrous benzene, TsOH, reflux, 5h; b). method A: NaOH in DMF, 160°C, 15h
 (16: 48%; 17: 10%); method B: 8% NaOH in MeOH, rt, 24h (16: 90%; 17: no detected)

Chart 4



a). Br₂-glacial HOAc, rt, 4h; b). SOCl₂-anhydrous benzene, rt, overnight;
 c). 5% KOH in EtOH, 50°C, 30min.

Chart 5


obtained in further study clearly indicated that cleavage of the C(12)–C(14) bond with aromatization of the D ring greatly depended on the structures of the substrates and the exact reaction conditions.

Accordingly, as an important part of our continuing synthetic study of the 12,13-*seco* norditerpenoid alkaloids, we have further studied the role of the structures of the A ring in the cleavage of the C(12)–C(14) bond of the C-nor compounds. Treatment of the C-nor compound **5** with 1.2 eq Br₂ in HOAc at room temperature for 4h afforded the 12,13-*seco* intermediate **21**, and the mixture of **22** and **23** in 20% and 60% yield, respectively. The molecular formula (C₂₄H₃₀NO₅Br) of compound **21** inferred from its HR-EI-MS and ¹³C-NMR spectra. Its ¹H- and ¹³C-NMR spectra showed an *exo*-methylene group double bond (δ_{H} 5.02, 5.53, each 1H, brs; δ_{C} 151.7 s, 110.0 t). Compounds **22** and **23** have the molecular formula C₂₃H₂₇NO₅ (HR-EI-MS) and

Table 2. ¹³C-NMR Data of Compounds **21**, **24**, **26**, **22/23**, **25** and **27**


No.	21	24	26	22/23	25	27
1	147.5 d	147.4 d	26.6 t	150.4 (149.7) d	149.5 d	27.1 t
2	132.7 d	132.8 d	39.5 t	132.2 (131.9) d	132.0 d	40.2 t
3	200.2 s	200.2 s	214.9 s	201.7 (201.6) s	200.8 s	217.6 s
4	50.7 s	50.4 s	45.6 s	51.6 (51.6) s	50.0 s	47.4 s
5	47.8 d	49.0 d	49.9 d	46.7 (46.3) d	47.3 d	45.5 d
6	91.9 d	91.7 d	93.5 d	91.7 (91.4) d	91.7 d	91.9 d
7	51.0 d	50.7 d	49.9 d	51.5 (52.2) d	51.3 d	47.7 d
8	139.4 s	139.5 s	140.2 s	138.4 (136.4) s	138.0 s	137.7 s
9	126.7 s	125.9 s	127.4 s	126.2 (127.9) s	127.0 s	127.7 s
10	46.0 d	49.0 d	45.2 d	151.6 (151.5) s	151.7 s	155.7 s
11	48.8 s	45.9 s	52.4 s	51.8 (51.8) s	51.8 s	52.0 s
12	36.2 t	45.9 t	47.8 t	110.3 (112.1) t	111.0 t	108.7 t
13	143.9 s	143.9 s	143.6 s	142.6 (143.0) s	144.2 s	143.9 s
14	106.9 d	106.9 d	106.5 d	111.6 (107.3) d	106.7 d	106.3 d
15	113.9 d	113.7 d	113.9 d	111.2 (111.0) d	110.7 d	110.7 d
16	145.1 s	145.0 s	144.8 s	144.4 (140.8) s	146.3 s	145.8 s
17	65.5 d	65.9 d	69.6 d	67.7 (67.9) d	68.0 d	72.3 d
18	71.4 t	71.3 t	72.8 t	71.7 (71.7) t	71.5 t	74.5 t
19	49.1 t	49.2 t	49.0 t	49.3 (49.1) t	49.1 t	48.9 t
21	50.8 t	50.6 t	50.9 t	50.9 (50.9) t	50.9 t	52.0 t
22	12.8 q	12.7 q	13.1 q	12.6 (12.5) q	12.8 q	12.8 q
6'	58.6 q	58.1 q	58.3 q	58.5 (58.9) q	58.6 q	58.3 q
16'	55.9 q	55.9 q	55.8 q	—	56.0 q	55.8 q
18'	59.1 q	58.5 q	58.9 q	59.2 (59.2) q	59.1 q	58.9 q

C₂₃H₂₆NO₅Br (HR-EI-MS), respectively. Their ¹H- and ¹³C-NMR spectra showed the presence of an *exo*-methylene group double bond and an α,β -unsaturated ketone (Table 2 and the Experimental). Cleavage of the C(12)–C(14) bond in **5** by the method recently reported from our laboratory¹⁾ gave the 12,13-*seco* product **24** in good yield (71%) and a clear-cut reaction (Chart 5). The molecular formula C₂₄H₃₀NO₅Cl of **24** can be established by its HR-EI-MS. Its structure was confirmed easy by comparison of the NMR data (Table 2) with **21**. Similarly, reaction of the C-nor compounds **6**, **16** (**17**) and **28** in the presence of only SOCl₂ in benzene instead of Br₂ in HOAc at room temperature resulted in the forma-



- a). SOCl_2 -anhydrous benzene, rt, overnight; b). 5% KOH in EtOH, rt, 2h;
c). Ac_2O -pyridine rt, 12h; d). SOCl_2 -anhydrous benzene, rt, overnight

Chart 6



- a). Ac_2O /pyridine, rt, 12h b). SOCl_2 -anhydrous benzene, rt, overnight; c). Na_2CO_3 in MeOH,
rt, overnight. d). 40% HBr, CH_2Cl_2 , r.t.; 2h; e). 40% HBr, CH_2Cl_2 , 80°C, 3h

Chart 7

tion of the 12,13-*seco* products **24**, **26**, and **30** in 100%, 40% and 66% yield, respectively (Charts 5, 6). But, when the similar reaction conditions were applied to the C-nor compound bearing the 1 α -OCH₃ group (**29**), the 12,13-*seco* compound **30** was obtained in 33% yield besides the by-products **31** and **32**. Both compounds **31** and **32** have the same molecular formula C₂₇H₃₉NO₇ (HR-EI-MS). Their ¹H- and ¹³C-NMR spectra showed characteristic signals at δ_{H} 5.34, 1H, br s; δ_{C} 145.3 s, 116.0 d for a trisubstituted double bond in **31**, δ_{C} 136.8 s, 134.2 s for a tetrasubstituted double bond in **32**. The former (**31**) was converted to **30** upon treatment with

Na_2CO_3 (Chart 7). The results of the studies mentioned above indicated the following points: 1). the 1 α -OCH₃ group of the C-nor molecules such as **9**, **10** could participate in the cleavage reaction but was not in itself necessary; 2). the α,β -unsaturated ketone or the 3-ketone of the A ring (e.g., **5** or **13**, **14**) also may enhance slightly the yields of the resulting products; 3). it is apparent that SOCl_2 in benzene instead of Br₂ in HOAc should be used in the cleavage C-nor compounds not bearing the 1-OCH₃ group.

The halogen-containing 12,13-*seco* norditerpenoid alkaloids such as **21**, **24** and **26** were subjected to treatment with

Table 3. ¹³C-NMR Data of Compounds **29**, **31**, **32**, **30**, **33** and **34**

No.	29	31	32	30	33	34
1	80.5 d	81.0 d	80.6 d	79.9	79.8 d	80.2 d
2	31.4 t	31.1 t	30.6 t	30.4	30.3 t	34.3 t
3	71.4 d	71.5 d	71.6 d	72.7	72.6 d	75.5 d
4	41.4 s	41.5 s	41.0 s	42.6	42.6 s	43.8 s
5	45.2 d	46.3 d	47.5 d	44.3	45.1 d	47.0 d
6	83.8 d	84.6 d	93.6 d	92.0	91.3 d	91.4 d
7	52.0 d	46.7 d	49.1 d	49.1	48.8 d	49.2 d
8	76.3 s	145.3 s	136.8 s	137.6	137.8 s	137.6 s
9	43.6 d	41.4 d	134.2 s	129.0	128.6 s	129.0 s
10	44.7 d	43.3 d	42.0 d	44.6	44.4 d	44.1 d
11	47.6 s	48.4 s	45.8 s	51.1	51.1 s	51.3 s
12	30.5 t	29.4 t	27.7 t	73.6	73.5 t	73.5 t
13	211.4 s	208.8 s	209.4 s	143.9	144.3 s	143.9 s
14	38.8 d	36.6 d	56.9 d	114.0	122.1 d	107.3 s
15	39.9 t	116.0 d	38.3 t	107.3	109.0 d	114.0 d
16	79.2 d	80.5 d	79.6 d	144.0	149.0 s	144.6 s
17	61.3 d	69.5 d	67.8 d	66.5	66.2 d	66.8 d
18	71.4 t	71.5 t	71.3 t	72.0	71.9 t	67.7 t
19	47.4 t	47.6 t	47.8 t	47.7	47.7 t	46.7 t
21	48.6 t	48.9 t	49.2 t	48.8	48.8 t	49.0 t
22	13.2 q	13.0 q	13.0 q	12.9	12.9 q	13.1 q
1'	56.1 q	56.2 q	55.9 q	—	—	—
6'	58.1 q	57.9 q	57.9 q	58.2	58.3 q	58.2 q
16'	58.2 q	58.4 q	58.3 q	55.9	55.8 q	56.0 q
18'	58.7 q	58.8 q	58.8 q	58.9	58.9 q	—
3-OAc	170.2 s	170.1 s	170.1 s	170.0	169.9 s	—
	21.1 q	21.0 q	21.0 q	21.0	21.0 q	—
13-OAc	—	—	—	—	168.9 s	—
	—	—	—	—	20.5 q	—

5% KOH in ethanol under conditions (room temperature, or 50 °C; 30 min or 2 h, respectively) resulting in elimination to produce the 12,13-*seco* compounds bearing the $\Delta^{10(12)}$ double bonds (**25**, **27**) in nearly quantitative yields (Charts 5, 6).

It is worthy of note that our attempts to cleavage of the tetrahydrofuran ring of **33** using a variety of reagents (*e.g.*, SeO₂, H₂/Pd-C, HClO₄ or HBr) were not successful. Only compounds **30** and **34** were obtained by reaction of **33** with 40% HBr in CH₂Cl₂ at room temperature for 2 h and 80 °C for 3 h, respectively (Chart 7). The molecular formula of both analogues **30** (C₂₆H₃₅NO₇) and **34** (C₂₃H₃₁NO₆) was determined by their HR-EI-MS. The structures of **30** and **34** were determined by comparison of the NMR spectra with the known compound **33**.¹⁾

In summary, we have continued to investigate further the nature of the stereoselectivity of the key cleavage reactions of C(12)–C(13) bonds and to develop practical protocols for this purpose. Meanwhile, a series of new norditerpenoid alkaloids were obtained. This is very useful for studies of the chemistry of this class of alkaloids.

Experimental

General Experimental Procedures Melting points are uncorrected. Optical rotations were measured with a JASCO DIP-370 polarimeter at 20 ± 1 °C. ¹H- and ¹³C-NMR spectra were measured on a Bruker AC-E 200 or a Varian INOVA-400/54 spectrometer, in CDCl₃ with tetramethylsilane (TMS) as internal standard; IR spectra were recorded on a Perkin-Elmer 983 spectrometer; MS were obtained with a VG Auto spec-3000 mass spectrometer; TLC was performed on silica gel GF₂₅₄ percolated plates, sprayed with a modified Dragendoff's reagent for detection; Column chromatography was carried out on Silica gel H (10–40 μm); All silica gel GF₂₅₄ and silica gel H used in the experiments were purchased from the Qingdao Sea Chemical.

Compound 2 To a solution of yunaconitine **1** (1066 mg, 1.62 mmol) in acetone (20 ml), Jone's reagent (1.75 ml, 4.85 mmol) was added dropwise under ice bath. After this, the solution was stirred for 20 min. Deluting (H₂O,

20 ml), basifying (NH₄OH, pH=11), extraction (CHCl₃, 20 ml×5), drying (Na₂SO₄) afforded the product as colorless needle crystals, 1063 mg (100%). *Rf* 0.72 (cyclohexane/acetone=1:1); mp 180–180.5 °C; IR (KBr) cm⁻¹: 3450 (OH), 2977, 2820, 1723 (COO), 1605, 1511, 1459, 1373, 1259, 1171, 1099; ¹H-NMR (200 MHz) δ: 0.98 (3H, t, *J*=7.2 Hz, NCH₂CH₃), 1.35 (3H, s, 8-OAc), 3.14, 3.14, 3.16, 3.52 (each 3H, s, OCH₃×4), 3.47, 3.69 (each 1H, ABq, *J*=8.2 Hz, H₂-18), 3.82 (3H, s, Ar-OCH₃), 4.06 (1H, d, *J*=6.0 Hz, H-6β), 4.89 (1H, d, *J*=5.2 Hz, H-14β), 6.89, 7.96 (each 2H, AA'BB', *J*=9.0 Hz, Ar-H); ¹³C-NMR (50 MHz) δ: 83.5 (d, C-1), 42.3 (t, C-2), 214.5 (s, C-3), 53.3 (s, C-4), 47.4 (d, C-5), 83.2 (d, C-6), 44.0 (d, C-7), 85.6 (s, C-8), 44.7 (d, C-9), 41.1 (d, C-10), 49.8 (s, C-11), 34.3 (t, C-12), 74.5 (s, C-13), 78.4 (d, C-14), 40.2 (t, C-15), 81.0 (d, C-16), 60.9 (d, C-17), 75.7 (t, C-18), 52.9 (t, 19) 47.6 (t, C-21), 12.5 (q, C-22), 56.0 (q, C-1'), 58.7 (q, C-6'), 57.8 (q, C-16'), 58.9 (q, C-18'), 165.7 (s, ArCO), 122.2, (s, C-1'), 131.5 (d, C-2'), 113.7 (d, C-3'), 5'), 163.4 (s, C-4'), 55.3 (q, ArOCH₃), 169.8 (s, OAc), 21.4 (q, OAc); EI-MS *m/z* (%) 657 (M⁺, 2), 642 (M-15, 2), 626 (M-31, 29), 625 (M-32, 66), 565 (100).

Compound 3 A solution of 3-dehydroyunaconitine (**2**) (1063 mg, 1.62 mmol) in 5% methanolic NaOH (25 ml) was heated at 55 °C for 30 min. Removal of solvent, deluting (H₂O, 10 ml), extraction (CHCl₃, 10 ml×5), drying (Na₂SO₄) and evaporation afforded the product as white amorphous powder, 726 mg (100%). *Rf* 0.33 (cyclohexane/acetone=1:1); IR (KBr) cm⁻¹: 3481 (OH), 2972, 2889, 2820, 1670 (CO), 1456, 1391, 1243, 1198, 1095, 1021, 970, 937, 752, 620; ¹H-NMR (200 MHz) δ: 1.02 (3H, t, *J*=6.8 Hz, NCH₂CH₃), 3.28, 3.37, 3.44 (each 3H, s, OCH₃×3), 4.11 (1H, d, *J*=6.8 Hz, H-6β), 4.23 (1H, d, *J*=6.4 Hz, H-14β), 6.23 (1H, d, *J*=10.2 Hz, H-2), 6.43 (1H, d, *J*=10.2 Hz, H-1); ¹³C-NMR (50 MHz) δ: 147.7 (d, C-1), 131.6 (d, C-2), 200.6 (s, C-3), 49.2 (s, C-4), 48.8 (d, C-5), 81.5 (d, C-6), 52.9 (d, C-7), 74.6 (s, C-8), 48.7 (d, C-9), 37.8 (d, C-10), 50.9 (s, C-11), 38.3 (t, C-12), 76.3 (s, C-13), 79.2 (d, C-14), 43.4 (t, C-15), 82.7 (d, C-16), 61.1 (d, C-17), 72.0 (t, C-18), 48.6 (t, C-19), 51.3 (t, C-21), 12.9 (q, C-22), 57.9 (q, C-6'), 58.0 (q, C-16'), 59.0 (q, C-18'); EI-MS *m/z* (%) 449 (M⁺, 100), 434 (M-15, 60), 418 (M-31, 75).

Compound 4 A mixture of compound **3** (450 mg, 1.0 mmol) in pyridine (30 ml) and MsCl (0.15 ml, 2.0 mmol) was stirred at room temperature for 4 h. Removal of solvent, basifying (10% Na₂CO₃), extraction (CHCl₃, 20 ml×5), drying (Na₂SO₄), evaporation and crystallization afforded the product as colorless needle crystals, 526 mg (100%). mp 111–111.5 °C; *Rf* 0.52 (cyclohexane/acetone=1:1); [α]_D²⁰ +106.0° (*c*=1.00, CHCl₃); IR (KBr) cm⁻¹: 3458 (OH), 2930, 2825, 1671 (CO), 1453, 1347, 1175, 1121, 1097, 981, 885; ¹H-NMR (200 MHz) δ: 0.96 (3H, t, *J*=7.0 Hz, NCH₂CH₃), 2.43 (2H, q, *J*=7.2 Hz, NCH₂CH₃), 3.11 (3H, s, 14-OSO₂CH₃), 3.23, 3.34, 3.41 (each 3H, s, OCH₃×3), 3.76, 3.85 (each 1H, ABq, *J*=8.0 Hz, H₂-18), 4.08 (1H, d, *J*=4.0 Hz, H-6β), 4.75 (1H, d, *J*=6.0 Hz, H-14β), 6.20 (1H, d, *J*=10.2 Hz, H-2), 6.37 (1H, d, *J*=10.2 Hz, H-1); ¹³C-NMR (50 MHz) δ: 146.6 (d, C-1), 132.0 (d, C-2), 200.4 (s, C-3), 49.4 (s, C-4), 48.7 (d, C-5), 81.6 (d, C-6), 53.8 (d, C-7), 74.6 (s, C-8), 47.3 (d, C-9), 37.6 (d, C-10), 50.8 (s, C-11), 37.6 (t, C-12), 74.7 (s, C-13), 85.2 (d, C-14), 42.9 (t, C-15), 82.0 (d, C-16), 60.6 (d, C-17), 71.9 (t, C-18), 48.8 (t, C-19), 51.4 (t, C-21), 12.8 (q, C-22), 58.2 (q, C-6'), 58.0 (q, C-16'), 59.0 (q, C-18'), 38.5 (q, OMs); EI-MS *m/z* (%) 527 (M⁺, 87), 512 (M-15, 35), 496 (M-31, 45), 449 (48); HR-EI-MS *m/z* 527.2187 (Calcd for C₂₅H₃₇NO₆S, 527.2189).

Compounds 5 and 6 Method A: To a solution of compound **4** (526 mg, 1.0 mmol) in DMF (30 ml), NaOH (100 mg) was added and the solution was heated at 150 °C for 6.5 h. Removal of solvent, deluting (H₂O), extraction (CHCl₃, 25 ml×3), drying (Na₂SO₄), evaporation and column chromatography (silica gel H, cyclohexane/acetone=3:1) afforded the pure products as white amorphous powder, **5** (290 mg, 68%) and **6** (20 mg, 5%).

Method B: A mixture of compound **4** (100 mg, 0.19 mmol) in 8% methanolic NaOH (5 ml) was stirred at room temperature for 24 h. Removal of solvent, deluting (H₂O), extraction (CHCl₃, 5 ml×4), drying (Na₂SO₄) and evaporation afforded the product as white amorphous powder **5**: 78 mg (95%); *Rf* 0.66 (cyclohexane/acetone=1:1); [α]_D²⁰ +105.9° (*c*=1.02, CHCl₃); IR (KBr) cm⁻¹: 3447 (OH), 2927, 2824, 1719 (CO), 1668 (CO), 1455, 1398, 1321, 1207, 1120, 973; ¹H-NMR (200 MHz) δ: 0.96 (3H, t, *J*=7.0 Hz, NCH₂CH₃), 3.26, 3.40, 3.48 (each 3H, s, OCH₃×3), 3.56, 3.86 (each 1H, ABq, *J*=8.4 Hz, H₂-18), 4.00 (1H, dd, *J*=6.0, 2.0 Hz, H-6β), 4.19 (1H, dd, *J*=13.0, 4.9 Hz, H-16β), 6.21 (1H, d, *J*=10.0 Hz, H-2), 6.26 (1H, d, *J*=10 Hz, H-1); ¹³C-NMR (50 MHz) δ see Table 1; EI-MS *m/z* (%) 431 (M⁺, 100), 416 (M-15, 50), 400 (M-31, 38) HR-EI-MS *m/z* 431.2282 (Calcd for C₂₄H₃₃NO₆, 431.2307); **6**: *Rf* 0.85 (cyclohexane/acetone=1:1); IR (KBr) cm⁻¹: 3532 (OH), 2930, 2826, 1712 (CO), 1667 (CO), 1457, 1384, 1310, 1187, 1113, 973; ¹H-NMR (200 MHz) δ: 0.92 (3H, t, *J*=7.2 Hz, NCH₂CH₃), 3.25, 3.34, 3.37 (each 3H, s, OCH₃×3), 3.66, 3.83 (each 1H, ABq,

$J=8.4$ Hz, H₂-18), 3.96 (1H, exchangeable in D₂O, 8-OH), 4.08 (1H, dd, $J=6.2, 2.2$ Hz, H-6 β), 6.19 (1H, d, $J=10.0$ Hz, H-2), 6.26 (1H, d, $J=10.0$ Hz, H-1); ¹³C-NMR (50 MHz) see Table 1; EI-MS m/z (%) 431 (M⁺, 100), 416 (M-15, 54), 400 (M-31, 60), 399 (60); HR-EI-MS m/z 431.2354 (Calcd for C₂₄H₃₃NO₆ 431.2307).

Compound 8 To a solution of pseudoaconine (7)⁵ (185 mg, 0.38 mmol) in pyridine (10 ml), MsCl (0.09 ml, 1.15 mmol) was added and the solution was stirred at room temperature for 2 h. Removal of solvent, basifying (10% Na₂CO₃), extraction (CHCl₃, 10 ml \times 3), drying (Na₂SO₄), evaporation and column chromatography (silica gel H, cyclohexane/acetone/diethylamine=4:2:0.1) afforded the product as white amorphous powder, 165 mg (78%); It was identified by comparison of TLC (silica gel G, R_f 0.31, cyclohexane/acetone=1:1) with the authentic sample.

Compounds 9 and 10 Method A: To a solution of Compound 8 (160 mg, 0.28 mmol) in DMF (8 ml), NaOH (30 mg) was added and the solution was heated at 150 °C for 24 h. Removal of solvent, deluting (H₂O, 8 ml), extraction (CHCl₃, 8 ml \times 3), drying (Na₂SO₄), evaporation and column chromatography (silica gel H, cyclohexane/acetone=5:1) afforded the pure products as white amorphous powder, 9 (95 mg, 70%) and 10 (20 mg, 15%).

Method B: A solution of Compound 8 (470 mg, 0.84 mmol) in pyridine (20 ml) was refluxed at 140 °C for 12 h. Removal of solvent and column chromatography (silica gel H, petroleum/acetone=3:1) afforded the products (9: colorless needle crystals, 12 mg, 3%; 10: white amorphous powder, 71 mg, 18%, besides the starting material (250 mg).

Method C: A solution of 14-methylsulfonyl pseudoaconine (10) (670 mg, 1.194 mmol) in 8% methanolic NaOH (35 ml) was stirred at room temperature for 12 h. Removal of solvent, deluting (H₂O, 30 ml), extraction (CHCl₃, 30 ml \times 3), drying (Na₂SO₄), evaporation and column chromatography (silica gel H, petroleum/acetone=3:1) afforded the product 9 as colorless needle crystals, 513 mg (92%) The structures of 9 and 10 were identified by comparison of TLC (cyclohexane/acetone=7:3, R_f 0.36 for 9; 0.63 for 10).

Compound 13 To a solution of Compound 11 (1.58 g, 3.50 mmol) in pyridine (50 ml), MsCl (0.55 ml, 7.10 mmol) was added and the solution was heated at 40 °C for 1.5 h. Removal of solvent, basifying (10% Na₂CO₃), extraction (CHCl₃, 25 ml \times 3), drying (Na₂SO₄) and evaporation in vacuum and crystallization (ether/acetone) afforded the pure product as colorless needle crystals, 1.86 g, (100%). mp 118.5–119 °C; R_f 0.60 (cyclohexane/acetone=1:1); $[\alpha]_D^{20} -51.1^\circ$ ($c=0.94$, CHCl₃); IR (KBr) cm⁻¹: 3505 (OH), 3324 (OH), 2962, 2894, 2836, 1720 (CO), 1454, 1343, 1180, 1092, 869; ¹H-NMR (200 MHz) δ : 0.97 (3H, t, $J=7.2$ Hz, NCH₂CH₃), 3.10 (3H, s, 14-OSO₂CH₃), 3.17, 3.34, 3.40 (each 3H, s, OCH₃ \times 3), 3.45, 3.84 (each 1H, ABq, $J=7.8$ Hz, H₂-18), 4.11 (1H, d, $J=6.4$ Hz, H-6 β), 4.71 (1H, d, $J=3.4$ Hz, H-14 β); ¹³C-NMR (50 MHz) δ : 24.9 (t, C-1), 38.5 (t, C-2), 217.4 (s, C-3), 53.0 (s, C-4), 44.1 (d, C-5), 82.3 (d, C-6), 52.7 (d, C-7), 74.5 (s, C-8), 47.6 (d, C-9), 40.3 (d, C-10), 45.7 (s, C-11), 37.1 (t, C-12), 74.7 (s, C-13), 85.4 (d, C-14), 43.1 (t, C-15), 82.0 (d, C-16), 64.5 (d, C-17), 75.5 (t, C-18), 48.3 (t, C-19), 52.9 (t, C-21), 12.8 (q, C-22), 58.2 (q, C-6'), 58.0 (q, C-16'), 59.0 (q, C-18'), 38.5 (q, OMs); EI-MS m/z (%) 529 (M⁺, 76), 514 (M-15, 63), 498 (M-31, 37), 469 (35), 454 (44), 438 (24); HR-EI-MS m/z 529.2351 (Calcd for C₂₅H₃₉NO₅S 529.2345).

Compounds 12 and 14 Method A: To a solution of compound 13 (213 mg, 0.40 mmol) in DMF (13 ml), NaOH (90 mg) was added and the solution was heated at 150 °C for 12 h. Removal of solvent, deluting (H₂O, 15 ml), extraction (CHCl₃, 15 ml \times 3), drying (Na₂SO₄), evaporation and column chromatography (silica gel H, petroleum/acetone=3:1) afforded the products as white amorphous powder (12: 65 mg, 37%; 14: 18 mg, 10%).

Method B: A solution of compound 13 (85 mg, 0.16 mmol) in 8% methanolic NaOH (5 ml) was stirred at room temperature for 24 h. Removal of solvent, deluting (H₂O, 5 ml), extraction (CHCl₃, 5 ml \times 3), drying (Na₂SO₄) and evaporation to dryness afforded the product as white amorphous powder (12: 70 mg, 100%), R_f 0.50 (cyclohexane/acetone=1:1). 12: $[\alpha]_D^{20} -23.3^\circ$ ($c=1.03$, CHCl₃); IR (KBr) cm⁻¹: 3447 (OH), 2928, 2853, 1716 (CO), 1455, 1113, 975; ¹H-NMR (200 MHz) δ : 0.97 (3H, t, $J=7.0$ Hz, NCH₂CH₃), 3.23, 3.39, 3.48 (each 3H, s, OCH₃ \times 3), 3.54, 3.65 (each 1H, ABq, $J=8$ Hz, H₂-18), 4.02 (1H, dd, $J=6.0, 2.2$ Hz, H-6 β), 4.18 (1H, dd, $J=13.0, 5.2$ Hz, H-16 α); ¹³C-NMR (50 MHz) see Table 1; EI-MS m/z (%) 433 (M⁺, 64), 418 (M-15, 100), 402 (M-31, 20); HR-EI-MS m/z 433.2449 (Calcd for C₂₄H₃₅NO₆ 433.2464); 14: R_f 0.78 (cyclohexane/acetone=1:1); $[\alpha]_D^{20} -24.7^\circ$ ($c=0.81$, CHCl₃); IR (KBr) cm⁻¹: 3517 (OH), 2922, 2853, 1716 (CO), 1456, 1377, 1196, 1111, 974; ¹H-NMR (200 MHz) δ : 0.97 (3H, t, $J=7.0$ Hz, NCH₂CH₃), 3.20, 3.29, 3.34 (each 3H, s, OCH₃ \times 3), 3.50, 3.72 (each 1H, ABq, $J=8.0$ Hz, H₂-18), 3.85 (1H, br s, exchangeable in D₂O, 8-OH), 4.05 (1H, dd, $J=6.0, 2.2$ Hz, H-6 β); ¹³C-NMR (50 MHz) see Table 1; EI-MS m/z (%) 433 (M⁺, 86), 418 (M-15, 100), 402 (M-31, 20); HR-EI-

MS m/z 433.2426 (Calcd for C₂₄H₃₅NO₆ 433.2464).

Compound 15 To a solution of compound 12 (500 mg, 0.95 mmol) in anhydrous benzene (30 ml), a mixture of TsOH (200 mg) and glycol (3 ml) was added and the solution was refluxed for 5 h under dropwise addition of benzene (50 ml) using a water separator. Basifying (10% Na₂CO₃, pH>9), separating the water layer, extraction (CHCl₃, 20 ml \times 2), drying (Na₂SO₄) and removal of solvent afforded the product as white amorphous powder, 511 mg, (95%). R_f 0.57 (ether/acetone=9:1); $[\alpha]_D^{20} +13.0^\circ$ ($c=0.77$, CHCl₃); IR (KBr) cm⁻¹: 3481 (OH), 2927, 1633, 1452, 1358, 1273, 1173, 1108, 1032, 979; ¹H-NMR (200 MHz) δ : 1.07 (3H, t, $J=7.0$ Hz, NCH₂CH₃), 3.09 (3H, s, 14-OSO₂CH₃), 3.23, 3.32, 3.39 (each 3H, s, OCH₃ \times 3), 3.46, 3.58 (each 1H, ABq, $J=9.2$ Hz, H₂-18), 3.86–4.00 (4H, m, O-CH₂-CH₂-O); ¹³C-NMR (50 MHz) δ : 28.2 (t, C-1), 30.6 (t, C-2), 112.7 (s, C-3), 45.3 (s, C-4), 46.8 (d, C-5), 82.3 (d, C-6), 53.4 (d, C-7), 73.9 (s, C-8), 47.8 (d, C-9), 40.7 (d, C-10), 45.6 (s, C-11), 36.8 (t, C-12), 74.8 (s, C-13), 85.8 (d, C-14), 42.9 (t, C-15), 82.8 (d, C-16), 63.4 (d, C-17), 73.5 (t, C-18), 48.7 (t, C-19), 50.6 (t, C-21), 13.4 (q, C-22), 58.1 (q, C-6'), 58.0 (q, C-16'), 58.9 (q, C-18'), 38.5 (q, OMs), 64.3 (t, OCH₂), 65.0 (t, OCH₂); EI-MS m/z (%) 573 (M⁺, 72), 558 (M-15, 51), 542 (M-31, 29), 528 (100), 486 (59); HR-EI-MS m/z 573.2568 (Calcd for C₂₇H₄₃NO₁₀S, 573.2607).

Compounds 16 and 17 Method A: To a solution of compound 15 (780 mg, 1.36 mmol) in DMF (60 ml), NaOH (375 mg) was added and the solution was heated at 160 °C for 15 h. Removal of solvent, deluting (H₂O, 50 ml), extraction (CHCl₃, 45 ml \times 3), drying (Na₂SO₄), evaporation to dryness and column chromatography (silica gel H, ether/acetone=95:5) afforded the pure products (16, colorless needle crystals, 310 mg, 48%; 17, white amorphous powder, 65 mg, 10%); 16: 0.49 (cyclohexane/acetone=1:1); $[\alpha]_D^{20} +70.6^\circ$ ($c=0.85$, CHCl₃); IR (KBr) cm⁻¹: 3453 (OH), 2923, 2811, 1717 (CO), 1633, 1450, 1379, 1200, 1161, 1109; ¹H-NMR (200 MHz) δ : 1.01 (3H, t, $J=7.0$ Hz, NCH₂CH₃), 3.25, 3.40, 3.52 (each 3H, s, OCH₃ \times 3), 3.8–4.0 (4H, m, OCH₂CH₂O), 4.15 (1H, dd, $J=13.4, 4.8$ Hz, H-16 β); ¹³C-NMR (50 MHz) see Table 1; EI-MS m/z (%) 477 (M⁺, 88), 462 (M-15, 68), 466 (M-31, 35), 432 (M-45, 100), 390 (87); HR-EI-MS m/z 477.2742 (Calcd for C₂₆H₃₉NO₇, 477.2726); 17: R_f 0.71 (cyclohexane/acetone=1:1); $[\alpha]_D^{20} +15.0^\circ$ ($c=1.33$, CHCl₃); IR (KBr) cm⁻¹: 3523 (OH), 2923, 2809, 1714 (CO), 1450, 1379, 1274, 1198, 1159, 1111, 1041, 947; ¹H-NMR (200 MHz) δ : 1.01 (3H, t, $J=7.0$ Hz, NCH₂CH₃), 3.23, 3.29, 3.36 (each 3H, s, OCH₃ \times 3), 3.82–3.97 (4H, m, OCH₂CH₂O); ¹³C-NMR (50 MHz) see Table 1; EI-MS m/z (%) 477 (M⁺, 51), 462 (M-16, 50), 445 (M-32, 37), 432 (M-45, 100), 391 (50); HR-EI-MS m/z 477.2738 (Calcd for C₂₆H₃₉NO₇, 477.2726).

Method B: A solution of compound 15 (90 mg, 0.16 mmol) in 8% methanolic NaOH (5 ml) was stirred at room temperature for 24 h. Removal of solvent, deluting (H₂O, 5 ml), extraction (CHCl₃, 5 ml \times 3), drying (Na₂SO₄) and evaporation to dryness afforded the product 16 as white amorphous powder, 67 mg (90%).

Compounds 21, 22 and 23 To a solution of compound 5 (280 mg, 0.65 mmol) in glacial acetic acid (7 ml), Br₂ (0.035 ml, 0.69 mmol) was added dropwise and the solution was stirred at room temperature 4 h. Basifying (saturated Na₂CO₃, pH>9), extraction (CHCl₃, 25 ml \times 3), drying (Na₂SO₄), removal of solvent and column chromatography (silica gel H, cyclohexane/acetone=3:1) afforded the pure products (21: white amorphous powder, 65 mg, 20%; 22+23: white amorphous powder, 170 mg, 60%). 21: R_f 0.63 (cyclohexane/acetone=7:3); $[\alpha]_D^{20} +142.8^\circ$ ($c=0.77$, CHCl₃); IR (KBr) cm⁻¹: 3408 (OH), 2924, 2852, 1671 (CO), 1510, 1457, 1400, 1303, 1211, 1106, 758; ¹H-NMR (200 MHz) δ : 0.93 (3H, t, $J=7.2$ Hz, NCH₂CH₃), 3.28, 3.33 (each 3H, s, OCH₃ \times 2), 3.90 (3H, s, Ar-OCH₃), 4.15 (1H, dd, $J=11.7, 3.5$ Hz, H-12), 6.42 (1H, d, $J=10.4$ Hz, H-1), 6.64 (1H, s, H-15), 6.88 (1H, s, H-14), 7.25 (1H, d, $J=10.4$ Hz, H-2); ¹³C-NMR (50 MHz) see Table 2; EI-MS m/z (%) 493 (M⁺, 50), 491 (M⁺, 50), 478 (M₁-15, 13), 476 (M₂-15, 13), 462 (M₁-31, 50), 460 (M₂-31, 50), 412 (M-Br, 100); HR-EI-MS m/z 491.1299 (Calcd for C₂₄H₃₅NO₃Br, 491.1307); 22: ¹H-NMR (200 MHz) δ : 0.95 (3H, t, $J=7.2$ Hz, NCH₂CH₃), 3.29, 3.31 (each 3H, s, OCH₃ \times 2), 4.92, 5.45 (each 1H, br s, H₂-12), 6.36 (1H, d, $J=10.0$ Hz, H-2), 6.68 (1H, s, H-15), 6.70 (1H, d, $J=10.0$ Hz, H-1), 7.08 (1H, s, H-14); ¹³C-NMR (50 MHz) see Table 2; EI-MS m/z (%) 397 (M⁺, 100), 382 (M-15, 34), 366 (M-31, 63); HR-EI-MS m/z 397.1900 (Calcd for C₂₃H₂₇NO₅, 397.1889); 23: ¹H-NMR (200 MHz) δ : 0.95 (3H, t, $J=7.2$ Hz, NCH₂CH₃), 3.29, 3.31 (each 3H, s, OCH₃ \times 2), 5.03, 5.53 (each 1H, br s, H₂-12), 6.37 (1H, d, $J=10.0$ Hz, H-2), 6.66 (1H, s, H-15), 6.68 (1H, d, $J=10.0$ Hz, H-1), 7.11 (1H, s, H-14); ¹³C-NMR (50 MHz) see Table 2; EI-MS m/z (%) 477 (M₁⁺, 17), 475 (M₂⁺, 17), 462 (M₁-15, 5), 460 (M₂-15, 5), 446 (M₁-31, 8), 444 (M₂-31, 7); HR-EI-MS m/z 475.1011 (Calcd for C₂₃H₂₆NO₃Br, 475.0994).

Compound 24 Method A: To a solution of compound **5** (35 mg, 0.08 mmol) in anhydrous benzene (2 ml), SOCl_2 (0.6 ml) was added and the solution was first stirred at room temperature overnight, to which then 10% Na_2CO_3 (2 ml) was added and stirred continuously for 5 min. Extraction (CHCl_3 , 3 ml \times 3), drying (Na_2SO_4), removal of solvent and column chromatography (silica gel H, cyclohexane/acetone=3:1) afforded the products as white amorphous powder, 21 mg (71%).

Method B: To a solution of compound **6** (23 mg, 0.05 mmol) in anhydrous benzene (1 ml), SOCl_2 (0.4 ml) was added dropwise and the solution was stirred at room temperature overnight. Basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 3 ml \times 3), drying (Na_2SO_4) and removal of solvent afforded the product as white amorphous powder, 25 mg (100%). *Rf* 0.73 (cyclohexane/acetone=1:1); $[\alpha]_D^{20}$ -4.4° ($c=0.45$, CHCl_3); IR (KBr) cm^{-1} : 3422 (OH), 2925, 2852, 1729 (CO), 1671 (CO), 1510, 1457, 1370, 1304, 1241, 1107, 1043, 978, 753; $^1\text{H-NMR}$ (200 MHz) δ : 0.94 (3H, t, $J=7.0$ Hz, NCH_2CH_3), 3.29, 3.34 (each 3H, s, $\text{OCH}_3\times 2$), 3.91 (3H, s, Ar-OCH₃), 4.12 (1H, dd, $J=12.6$, 1.8 Hz, H-12), 4.30 (1H, dd, $J=12.6$, 3.4 Hz, H-12), 6.42 (1H, d, $J=10.4$ Hz, H-1), 6.65 (1H, s, H-15), 6.92 (1H, s, H-14), 7.21 (1H, d, $J=10.4$ Hz, H-2); $^{13}\text{C-NMR}$ (50 MHz) see Table 2; EI-MS m/z (%) 449 (M^+ , 11), 447 (M_2 , 29), 411 (M-HCl, 100); HR-EI-MS m/z 447.1821 (Calcd for $\text{C}_{24}\text{H}_{30}\text{NO}_5\text{Cl}$, 447.1812).

Compound 25 Method A: A solution of compound **21** (30 mg, 0.06 mmol) in 5% ethanolic KOH (2 ml) was heated at 50 °C for 30 min. Removal of solvent, deluting (H_2O , 3 ml), extraction (CHCl_3 , 3 ml \times 3), drying (Na_2SO_4) and evaporation afforded the product as white amorphous powder, 25 mg (100%).

Method B: A solution of compound **24** (25 mg, 0.056 mmol) in 5% ethanolic KOH (2 ml) was heated at 50 °C for 30 min. Removal of solvent, deluting (H_2O , 3 ml) extraction (CHCl_3 , 3 ml \times 3), drying (Na_2SO_4) and evaporation afforded the product as white amorphous powder, 23 mg (100%). *Rf* 0.70 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+120.4^\circ$ ($c=0.98$, CHCl_3); IR (KBr) cm^{-1} : 3420 (OH), 2925, 2853, 1716 (CO), 1672 (CO), 1608, 1504, 1455, 1350, 1307, 1207, 1109; $^1\text{H-NMR}$ (200 MHz) δ : 0.93 (3H, t, $J=7.2$ Hz, NCH_2CH_3), 2.55 (2H, q, $J=7.2$ Hz, NCH_2CH_3), 2.45, 2.66 (each 1H, ABq, $J=10.4$ Hz, H₂-19), 2.63 (1H, brs, H-17), 2.91 (1H, d, $J=6.4$ Hz, H-5), 3.21 (1H, d, $J=1.4$ Hz, H-7), 3.29, 3.34 (each 3H, s, $\text{OCH}_3\times 2$), 3.68, 3.90 (each 1H, ABq, $J=10.0$ Hz, H₂-18), 3.72 (1H, d, $J=6.2$ Hz, H-6 β), 3.93 (3H, s, Ar-OCH₃), 5.02, 5.53 (each 1H, brs, H₂-12), 6.36 (1H, d, $J=10.0$ Hz, H-2), 6.68 (1H, s, H-15), 7.10 (1H, d, $J=10.0$ Hz, H-1), 7.15 (1H, s, H-14); $^{13}\text{C-NMR}$ (50 MHz) δ : see Table 2; EI-MS m/z (%) 411 (M^+ , 100), 396 (M-15, 43), 380 (M-31, 65), 366 (44); HR-EI-MS m/z 411.2052 (Calcd for $\text{C}_{24}\text{H}_{29}\text{NO}_5$, 411.2045).

Compound 26 To a solution of compound **16** or compound **17** (100 mg, 0.21 mmol) in anhydrous benzene (5 ml), SOCl_2 (0.5 ml) was added dropwise and the solution was stirred at room temperature overnight. Removal of solvent, basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 5 ml \times 3), drying (Na_2SO_4), evaporation and column chromatography (silica gel H, cyclohexane/acetone=3:1) afforded the product as white amorphous powder, 30 mg (40%). *Rf* 0.83 (cyclohexane/acetone=1:1); $[\alpha]_D^{20}$ $+48.3^\circ$ ($c=0.58$, CHCl_3); IR (KBr) cm^{-1} : 3425 (OH), 2927, 2852, 1714 (CO), 1627, 1510, 1453, 1372, 1241, 1206, 1106; $^1\text{H-NMR}$ (400 MHz) δ : 1.01 (3H, t, $J=6.8$ Hz, NCH_2CH_3), 2.56 (2H, q, $J=6.8$ Hz, NCH_2CH_3), 3.27, 3.28 (each 3H, s, $\text{OCH}_3\times 2$), 3.90 (3H, s, Ar-OCH₃), 6.61 (1H, s, H-15), 6.88 (1H, s, H-14); $^{13}\text{C-NMR}$ (100 MHz) see Table 2; EI-MS m/z (%) 451 (M_1^+ , 15), 449 (M_2^+ , 45), 420 (M_1-31 , 50), 418 (M_2-31 , 100); HR-EI-MS m/z 449.1972 (Calcd for $\text{C}_{24}\text{H}_{32}\text{NO}_5\text{Cl}$, 449.1969).

Compound 27 A solution of compound **26** (45 mg, 0.1 mmol) in 5% ethanolic KOH (3 ml) was stirred at room temperature for 2 h overnight. Removal of solvent, deluting (H_2O , 5 ml), extraction (CHCl_3 , 5 ml \times 3), drying (Na_2SO_4) and evaporation to dryness afforded the product as white amorphous powder, 43 mg (100%). *Rf* 0.52 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+144.5^\circ$ ($c=1.01$, CHCl_3); IR (KBr) cm^{-1} : 3451 (OH), 2928, 2845, 1714 (CO), 1610, 1502, 1451, 1351, 1308, 1246, 1209, 1109, 966, 876; $^1\text{H-NMR}$ (200 MHz) δ : 0.97 (3H, t, $J=7.2$ Hz, NCH_2CH_3), 3.22, 3.30 (each 3H, s, $\text{OCH}_3\times 2$), 3.91 (3H, s, 16-OCH₃), 3.55, 3.72 (each 1H, ABq, $J=8.0$ Hz, H₂-18), 5.25, 5.47 (each 1H, brs, H₂-12), 6.64 (1H, s, H-15), 7.08 (1H, s, H-14); $^{13}\text{C-NMR}$ (50 MHz) see Table 2; EI-MS m/z (%) 413 (M_1^+ , 60), 398 (M-15, 13), 382 (M-31, 100); HR-EI-MS m/z 413.2210 (Calcd for $\text{C}_{24}\text{H}_{31}\text{NO}_5$, 413.2202).

Compound 28 To a solution of compound **10** (242 mg, 0.52 mmol) in pyridine (5 ml), Ac_2O (1 ml) was added and the solution was stirred at room temperature for 2 h. Removal of solvent, basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 5 ml \times 3), drying (Na_2SO_4) and evaporation afforded the product as white amorphous powder, 262 mg (100%). *Rf* 0.72 (cyclo-

hexane/acetone=7:3); $[\alpha]_D^{20}$ $+34.9^\circ$ ($c=0.63$, CHCl_3); $^1\text{H-NMR}$ (200 MHz) δ : 1.07 (3H, t, $J=7.2$ Hz, NCH_2CH_3), 2.06 (H, s, OAc), 3.15, 3.22, 3.32, 3.37 (each 3H, s, $\text{OCH}_3\times 4$), 2.93, 3.87 (each 1H, ABq, $J=8.6$ Hz, H₂-18), 4.29 (1H, brs, exchangeable in D_2O , 8-OH), 4.91 (1H, dd, $J=12.6$, 5.0 Hz, H-3 β); IR (KBr) cm^{-1} : 3519 (OH), 2927, 2822, 1734 (COO), 1716 (CO), 1452, 1378, 1244, 1101, 974; $^{13}\text{C-NMR}$ (50 MHz) δ : 80.9 (d, C-1), 31.5 (t, C-2), 71.7 (d, C-3), 41.4 (s, C-4), 45.4 (d, C-5), 83.4 (d, C-6), 50.4 (d, C-7), 73.0 (s, C-8), 47.1 (d, C-9), 44.3 (d, C-10), 47.7 (s, C-11), 31.3 (t, C-12), 209.3 (s, C-13), 36.4 (d, C-14), 37.7 (t, C-15), 80.8 (d, C-16), 61.2 (d, C-17), 71.7 (t, C-18), 47.4 (t, C-19), 48.7 (t, C-21), 13.3 (q, C-22), 56.1 (q, C-1'), 57.9 (q, C-6'), 58.2 (q, C-16'), 58.8 (q, C-18'), 170.2 (s, OAc), 21.1 (q, OAc); EI-MS m/z (%) 507 (M^+ , 9), 492 (M-15, 6), 476 (M-31, 100), 448 (89), 416 (83); HR-EI-MS m/z 507.2819 (Calcd for $\text{C}_{27}\text{H}_{41}\text{NO}_8$, 507.2832).

Compound 29 To a solution of compound **9** (120 mg, 0.25 mmol) in pyridine (3 ml), Ac_2O (0.5 ml) was added and the solution was stirred at room temperature for 2 h. Removal of solvent, basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 5 ml \times 3), drying (Na_2SO_4) and evaporation to dryness afforded the product as white amorphous powder, 130 mg (100%). *Rf* 0.50 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+45.3^\circ$ ($c=1.06$, CHCl_3); IR (KBr) cm^{-1} : 3446 (OH), 2930, 2822, 1733 (COO), 1718 (CO), 1454, 1371, 1246, 1204, 1164, 1103, 1032, 979, 936; $^1\text{H-NMR}$ (200 MHz) δ : 1.03 (3H, t, $J=7.0$ Hz, NCH_2CH_3), 2.02 (3H, s, OAc), 3.11, 3.18, 3.34, 3.46 (each 3H, s, $\text{OCH}_3\times 4$), 2.89, 3.72 (each 1H, ABq, $J=8.8$ Hz, H₂-18), 3.97 (1H, d, $J=6.4$ Hz, H-6 β), 4.87 (1H, dd, $J=12.1$, 5.4 Hz, H-3 β); $^{13}\text{C-NMR}$ (50 MHz) see Table 3; EI-MS m/z (%) 507 (M^+ , 13), 492 (M-15, 14), 496 (M-31, 100), 448 (89), 416 (90); HR-EI-MS m/z 507.2833 (Calcd for $\text{C}_{27}\text{H}_{41}\text{NO}_8$, 507.2832).

Compounds 30, 31 and 32 To a solution of compound **29** (346 mg, 0.68 mmol) in anhydrous benzene (18 ml), SOCl_2 (1.8 ml) was added dropwise and the solution was stirred at room temperature for 2 h. Basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 20 ml \times 3), drying (Na_2SO_4), removal of solvent and column chromatography (silica gel H, petroleum/acetone=5:1) afforded the products as white amorphous powder. **30**: 106 mg (33%); *Rf* 0.48 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+160.0^\circ$ ($c=0.15$, CHCl_3); IR (KBr) cm^{-1} : 3426 (OH), 2926, 2854, 1736 (COO), 1621, 1507, 1456, 1372, 1240, 1105, 1025, 989; $^1\text{H-NMR}$ (200 MHz) δ : 1.02 (3H, t, $J=7.0$ Hz, NCH_2CH_3), 2.07 (3H, s, OAc), 3.20, 3.31 (each 3H, s, $\text{OCH}_3\times 2$), 3.84 (3H, s, Ar-OCH₃), 4.36 (1H, dd, $J=10.0$, 8.4 Hz, H-12 β), 5.13 (1H, dd, $J=11.4$, 5.0 Hz, H-3 β), 5.60 (1H, brs, exchangeable in D_2O , 13-OH); 6.50 (1H, s, H-15), 6.56 (1H, s, H-14); $^{13}\text{C-NMR}$ (50 MHz) see Table 3; EI-MS m/z (%) 473 (M^+ , 67), 458 (M-15, 40), 442 (M-31, 100); HR-EI-MS m/z 473.2407 (Calcd for $\text{C}_{26}\text{H}_{35}\text{NO}_7$, 473.2413). **31**: 65 mg (20%); *Rf* 0.58 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+155.0^\circ$ ($c=0.40$, CHCl_3); IR (KBr) cm^{-1} : 2926, 2854, 1733 (COO), 1637, 1456, 1371, 1243, 1106, 1032, 980; $^1\text{H-NMR}$ (200 MHz) δ : 1.04 (3H, t, $J=7.0$ Hz, NCH_2CH_3), 2.06 (3H, s, OAc), 3.16, 3.21, 3.33, 3.51 (each 3H, s, $\text{OCH}_3\times 4$), 2.93, 3.86 (each 1H, ABq, $J=8.8$ Hz, H₂-18), 4.01 (1H, d, $J=6.6$ Hz, H-6 β), 4.90 (1H, dd, $J=11.8$, 5.0 Hz, H-3 β), 5.34 (1H, brs, H-15); $^{13}\text{C-NMR}$ (50 MHz) see Table 3; EI-MS m/z (%) 489 (M^+ , 55), 474 (M-15, 39), 458 (M-31, 100); HR-EI-MS m/z 489.2734 (Calcd for $\text{C}_{27}\text{H}_{39}\text{NO}_7$, 489.2726). **32**: 65 mg (20%); *Rf* 0.62 (cyclohexane/acetone=7:3); $[\alpha]_D^{20}$ $+46.8^\circ$ ($c=0.94$, CHCl_3); IR (KBr) cm^{-1} : 2935, 2827, 1729 (COO), 1645, 1452, 1372, 1243, 1105, 1031, 981; $^1\text{H-NMR}$ (200 MHz) δ : 1.05 (3H, t, $J=7.0$ Hz, NCH_2CH_3), 2.06 (3H, s, OAc), 3.19, 3.20, 3.30, 3.48 (each 3H, s, $\text{OCH}_3\times 4$), 2.91, 3.86 (each 1H, ABq, $J=8.8$ Hz, H₂-18), 4.20 (1H, dd, $J=9.6$, 7.2 Hz, H-14 β), 4.93 (1H, dd, $J=11.8$, 5.8 Hz, H-3 β); $^{13}\text{C-NMR}$ (50 MHz) see Table 3; EI-MS m/z 489 (M^+ , 75), 474 (M-15, 100), 496 (M-31, 78); HR-EI-MS m/z 489.2707 (Calcd for $\text{C}_{27}\text{H}_{39}\text{NO}_7$, 489.2726).

Compound 30 Method A: A solution of compound **31** (55 mg, 0.10 mmol) in saturated methanolic Na_2CO_3 (3 ml) was stirred at room temperature overnight. Removal of solvent, deluting (H_2O , 5 ml), extraction (CHCl_3 , 5 ml \times 3), drying (Na_2SO_4) and evaporation afforded the product as white amorphous powder, 51 mg (99%).

Method B: A solution of compound **33** (70 mg, 0.13 mmol) in 20% acetic HClO_4 (7 ml) was heated at 80 °C for 5 h. Basifying (saturated Na_2CO_3 , pH>9), extraction (CHCl_3 , 5 ml \times 5), drying (Na_2SO_4), removal of solvent and column chromatography (silica gel H, cyclohexane/acetone=5:1) afforded the product as white amorphous powder, 32 mg (58%).

Method C: A mixed solution of compound **28** (242 mg, 0.048 mmol) in anhydrous benzene (10 ml) and SOCl_2 (1 ml) was stirred at room temperature overnight. Basifying (10% Na_2CO_3 , pH>9), extraction (CHCl_3 , 10 ml \times 5), drying (Na_2SO_4), removal of solvent gave a residue (260 mg), which was chromatographed over silica gel H (8 g) eluting with cyclohexane-acetone (5:1) to afford the product as white amorphous powder, **30** (140 mg, 66%).

Compound 33 A mixture of compound **18** (120 mg, 0.27 mmol) in pyridine (5 ml) and Ac₂O (0.5 ml, 4.5 mmol) was stirred at room temperature for 20 h. Removal of solvent, column chromatography (silica gel H, cyclohexane/acetone=6:1) and crystallization (95% EtOH) afforded the product as colorless needle crystals, 80 mg (54%). It was identified by comparison of TLC (silica gel G, cyclohexane/acetone=7:3, *R_f* 0.45) with the authentic sample.

Compound 34 To a solution of compound **33** (17 mg, 0.03 mmol) in CH₂Cl₂ (3 ml), 49% HBr (6 drops) was added and the solution was heated at 80 °C for 3 h. Basifying (10% Na₂CO₃, pH>9), extraction (CHCl₃, 5 ml×5), drying (Na₂SO₄), evaporation to dryness afforded the product as white amorphous powder, 13 mg (100%). *R_f* 0.22 (cyclohexane/acetone=7:3); [α]_D²⁰ +28.3° (*c*=1.13, CHCl₃); IR (KBr) cm⁻¹: 3365 (OH), 2926, 2854, 1618, 1508, 1459, 1378, 1273, 1230, 1169, 1104, 1012, 870, 759; ¹H-NMR (400 MHz) δ : 1.05 (3H, t, *J*=7.2 Hz, NCH₂CH₃), 3.33 (3H, s, OCH₃), 3.87 (3H, s, Ar-OCH₃), 4.38 (1H, t, *J*=8.4 Hz, H-12 β), 5.51 (1H, br s, 13-OH), 6.53, 6.60 (each 1H, s, Ar-H); ¹³C-NMR (200 MHz) see Table 3; EI-MS *m/z*

(%) 417 (M⁺, 34), 403 (M-14, 29), 402 (M-15, 28), 386 (100); HR-EI-MS *m/z* 417.2143 (Cald for C₂₃H₃₁NO₆, 417.2151).

Acknowledgements Financial support for this research was provided from the National Science Foundation of China (No. 3007088). We are grateful to Prof. Xiao-Tian Liang for his advice on this manuscript.

References and Notes

- 1) Wang F. P., Chen Q. H., Li B. G., *Tetrahedron*, **57**, 4705—4712 (2001).
- 2) Wang F. P., Chen Q. H., Li Z. B., Li B. G., *Chem. Pharm. Bull.*, **49**, 689—694 (2001).
- 3) Chen Q. H., Wang F. P., Yu K. B., *Chin. Chem. Lett.*, **11**, 689—692 (2000).
- 4) Zhang R. P., Chen S. Y., Zhou J., *Acta Bota. Yunnanica.*, **20**, 474—478 (1998).
- 5) The known compound **7** was prepared from **1** by alkaline hydrolysis.